公开(公告)号：US12122815B2

公开(公告)日：2024-10-22

申请号：US17279266

申请日：2019-09-24

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Hiroshi Imoto ,  Mari Adachi ,  Yoko Kanematsu ,  Taiji Asami ,  Ayumu Niida ,  Naoki Nishizawa ,  Derek Cecil Cole ,  Mack Flinspach ,  Nick Scorah ,  Abhijit Suresh Bhat

IPC分类号： C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K38/00 ,  A61K47/02 ,  A61P1/08

CPC分类号： C07K14/575 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2059 ,  A61K47/02 ,  A61P1/08 ,  A61K38/00

摘要： The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 328-893.

公开(公告)号：US12122778B2

公开(公告)日：2024-10-22

申请号：US17277425

申请日：2019-09-19

申请人： Novo Nordisk Health Care AG

发明人： Xiaozhang Zheng ,  Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, Jr. ,  Jian Lin ,  Lorna Mitchell ,  David Richard ,  Tatiana Shelekhin

IPC分类号： C07D487/04 ,  A61K9/00

CPC分类号： C07D487/04 ,  A61K9/0053

摘要： The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).

公开(公告)号：US12122753B2

公开(公告)日：2024-10-22

申请号：US16961230

申请日：2019-01-10

申请人： MetrioPharm AG

发明人： Ingo Saar ,  Wolfgang Brysch ,  Jörg von Wegerer

IPC分类号： C07D237/32 ,  A61K47/22 ,  A61K9/00

CPC分类号： C07D237/32 ,  A61K47/22 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053

摘要： The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.

公开(公告)号：US12121614B2

公开(公告)日：2024-10-22

申请号：US18300739

申请日：2023-04-14

申请人： VICORE PHARMA AB

发明人： Ola Camber ,  Christina Johansson

IPC分类号： A61K9/28 ,  A61K9/00 ,  A61K9/48 ,  A61K31/4178

CPC分类号： A61K9/4866 ,  A61K9/0056 ,  A61K9/4808 ,  A61K9/4825 ,  A61K31/4178

摘要： According to the invention there is provided a pharmaceutical composition comprising N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, in which composition the C21 or salt thereof is protected by the presence of a coating comprising an enteric substance. Preferred dosage forms comprise capsules in which C21 or salt thereof is presented in the form of a dry powder mixture or a suspension of particles of C21 in a solvent in which it is insoluble. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.

公开(公告)号：US12121571B2

公开(公告)日：2024-10-22

申请号：US17078376

申请日：2020-10-23

申请人： Jazz Pharmaceuticals Ireland Ltd.

发明人： Mi Rim Choi ,  Tong Lin ,  Jeffrey Silverman

IPC分类号： A61K38/50 ,  A61K9/00 ,  A61P1/00

CPC分类号： A61K38/50 ,  A61K9/0019 ,  A61P1/00 ,  C12Y305/01001

摘要： The present invention provides compositions and methods for treating a disease treatable by asparagine depletion in a human subject comprising administering to a human subject a recombinant L-asparaginase.

公开(公告)号：US12121570B2

公开(公告)日：2024-10-22

申请号：US18464583

申请日：2023-09-11

申请人： Babak Azizzadeh

发明人： Babak Azizzadeh

IPC分类号： A61K38/48 ,  A61K9/00 ,  A61P25/22

CPC分类号： A61K38/4893 ,  A61K9/0019 ,  A61P25/22

摘要： Herein disclosed are improved methods for treating stress disorders, such as Post-Traumatic Stress Disorder and perceived stress, by administration of acetylcholine release inhibitors, such as neurotoxic proteins (e.g., a botulinum toxin), to a patient at specific locations and amounts.

公开(公告)号：US12121549B2

公开(公告)日：2024-10-22

申请号：US16642741

申请日：2017-08-29

申请人： BGI SHENZHEN

发明人： Zhuye Jie ,  Suisha Liang ,  Huihua Xia ,  Yuanqiang Zou ,  Liang Xiao ,  Huijue Jia

IPC分类号： A61K35/74 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K45/06 ,  A61P9/10

CPC分类号： A61K35/74 ,  A61K9/0053 ,  A61P9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K45/06

摘要： The present invention discloses an application of Alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases, for example but not limited to, atherosclerosis related diseases, cardiovascular diseases and obesity.

公开(公告)号：US12121538B2

公开(公告)日：2024-10-22

申请号：US17319292

申请日：2021-05-13

申请人： AMORPHICAL LTD.

发明人： Yosef Ben ,  Yigal Dov Blum

IPC分类号： A61K33/10 ,  A61K9/00 ,  A61K9/10 ,  A61K9/14 ,  A61K47/24 ,  A61P31/00 ,  A61P35/00

CPC分类号： A61K33/10 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/0073 ,  A61K9/10 ,  A61K9/143 ,  A61K47/24 ,  A61P31/00 ,  A61P35/00

摘要： The present invention provides compositions comprising amorphous calcium carbonate (ACC), suitable to being administered by inhalation, and methods for their use in treating ACC-responsive diseases and conditions. Kits for preparing suspension compositions of the present invention are provided as well.

公开(公告)号：US20240343834A1

公开(公告)日：2024-10-17

申请号：US18507778

申请日：2023-11-13

申请人： Seagen Inc. ,  The General Hospital Corporation

发明人： David A. Eavarone ,  Jeffrey Behrens ,  Jillian M. Prendergast ,  Bo R. Rueda ,  Rosemary Foster ,  Kristen D. Starbuck

IPC分类号： C07K16/44 ,  A61K9/00 ,  A61K31/00 ,  A61K31/337 ,  A61K31/555 ,  A61K33/242 ,  A61K33/243 ,  A61K33/244 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  G01N33/574

CPC分类号： C07K16/44 ,  A61K9/0019 ,  A61K31/00 ,  A61K31/337 ,  A61K31/555 ,  A61K33/242 ,  A61K33/243 ,  A61K39/39558 ,  A61K47/68031 ,  A61K47/6851 ,  A61K47/6869 ,  A61P35/00 ,  G01N33/57449 ,  A61K33/244 ,  A61K2039/505 ,  C07K2317/73 ,  G01N2400/00 ,  G01N2400/02

摘要： Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

公开(公告)号：US20240343805A1

公开(公告)日：2024-10-17

申请号：US18633748

申请日：2024-04-12

申请人： Incyte Corporation

发明人： Liang-Chuan Wang ,  Chifei Sun ,  Ekaterine Asatiani

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61P35/00 ,  C07K16/2863 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/565

摘要： The present disclosure describes a bispecific antibody targeting human programmed death-1 (PD-1) and human transforming growth factor β receptor 2 (TGFβR2) for use in the treatment of disorder such as non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), ovarian cancer, breast cancer, bladder cancer, renal cell carcinoma, melanoma, gastric adenocarcinoma, esophageal cancer, gastroesophageal adenocarcinoma, malignant pleural mesothelioma, pancreatic adenocarcinoma, and colorectal cancer (CRC).